Valeo Pharma Inc
Valeo Pharma Inc. operates as a pharmaceutical company focused on licensing, acquiring, and commercializing drugs. The company provides commercialized pharmaceutical products in Canada, with a focus on respiratory/allergy, ophthalmology, and specialty therapeutic areas. It licenses and acquires Canadian rights to commercial-stage and proprietary drugs, managing registration and commercialization … Read more
Valeo Pharma Inc (VPHIF) - Net Assets
Latest net assets as of July 2024: $-63.03 Million USD
Based on the latest financial reports, Valeo Pharma Inc (VPHIF) has net assets worth $-63.03 Million USD as of July 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($32.20 Million) and total liabilities ($95.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-63.03 Million |
| % of Total Assets | -195.79% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 387.03 |
Valeo Pharma Inc - Net Assets Trend (2016–2023)
This chart illustrates how Valeo Pharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Valeo Pharma Inc (2016–2023)
The table below shows the annual net assets of Valeo Pharma Inc from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-10-31 | $-40.34 Million | -126.00% |
| 2022-10-31 | $-17.85 Million | -969.36% |
| 2021-10-31 | $2.05 Million | -33.11% |
| 2020-10-31 | $3.07 Million | +14050.00% |
| 2019-10-31 | $-22.00K | +98.39% |
| 2018-10-31 | $-1.37 Million | +47.45% |
| 2017-10-31 | $-2.60 Million | -372.30% |
| 2016-10-31 | $955.75K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Valeo Pharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13809.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.70 Million | % |
| Other Comprehensive Income | $-307.00K | % |
| Other Components | $10.54 Million | % |
| Total Equity | $-40.34 Million | 100.00% |
Valeo Pharma Inc Competitors by Market Cap
The table below lists competitors of Valeo Pharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fast Casual Concepts Inc
PINK:FCCI
|
$9.87K |
|
Mastern Premier REIT 1 Co. Ltd.
KO:357430
|
$9.87K |
|
RPAD5F
SA:RPAD5F
|
$9.87K |
|
CFAGF
OTCGREY:CFAGF
|
$9.87K |
|
FAN MILK LTD.
GSE:FML
|
$9.86K |
|
coinIX GmbH & Co. KGaA
DU:XCX
|
$9.86K |
|
FREEGOLD VENT
BE:FR4N
|
$9.86K |
|
CHINA AVIATION OIL
BE:VZ8
|
$9.86K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Valeo Pharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -17,848,000 to -40,337,000, a change of -22,489,000.
- Net loss of 27,808,000 reduced equity.
- New share issuances of 3,920,000 increased equity.
- Other comprehensive income decreased equity by 106,000.
- Other factors increased equity by 1,505,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-27.81 Million | -68.94% |
| Share Issuances | $3.92 Million | +9.72% |
| Other Comprehensive Income | $-106.00K | -0.26% |
| Other Changes | $1.50 Million | +3.73% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Valeo Pharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-10-31 | $0.02 | $0.05 | x |
| 2017-10-31 | $-0.05 | $0.05 | x |
| 2018-10-31 | $-0.03 | $0.05 | x |
| 2019-10-31 | $0.00 | $0.05 | x |
| 2020-10-31 | $0.05 | $0.05 | x |
| 2021-10-31 | $0.03 | $0.05 | x |
| 2022-10-31 | $-0.22 | $0.05 | x |
| 2023-10-31 | $-0.47 | $0.05 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Valeo Pharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -51.58%
- • Asset Turnover: 1.31x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-122.75%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -133.56% | -129.50% | 0.23x | 4.46x | $-1.37 Million |
| 2017 | 0.00% | -283.27% | 0.38x | 0.00x | $-3.36 Million |
| 2018 | 0.00% | -55.62% | 1.29x | 0.00x | $-2.30 Million |
| 2019 | 0.00% | -54.96% | 1.13x | 0.00x | $-3.61 Million |
| 2020 | -155.13% | -63.73% | 0.68x | 3.57x | $-5.07 Million |
| 2021 | -693.28% | -104.99% | 0.64x | 10.24x | $-14.44 Million |
| 2022 | 0.00% | -92.80% | 0.48x | 0.00x | $-23.96 Million |
| 2023 | 0.00% | -51.58% | 1.31x | 0.00x | $-23.77 Million |
Industry Comparison
This section compares Valeo Pharma Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $439,452,927
- Average return on equity (ROE) among peers: -31.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Valeo Pharma Inc (VPHIF) | $-63.03 Million | -133.56% | N/A | $9.87K |
| Ascend Wellness Holdings Inc (AAWH) | $71.80 Million | -118.37% | 11.54x | $48.90 Million |
| AB Science S.A (ABSCF) | $-21.01 Million | 0.00% | 0.00x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $-294.68K | 0.00% | 0.00x | $603.58K |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $195.20 Million |
| Acreage Holdings Inc (ACRDF) | $494.79 Million | -30.37% | 0.40x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $29.91 Million | 0.00% | 0.07x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.72 Million | -18.78% | 0.11x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $20.08 Million | -10.91% | 0.33x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $21.19 Million | 12.93% | 1.96x | $1.85 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.25 Billion | 5.19% | 0.72x | $85.61 Million |